HollyF.LoftonMDDABOM
Internal Medicine • New York, NYObesity Medicine & Nutrition
Clinical Associate Professor, Medicine and Surgery, New York University School of Medicine, Director, Medical Weight Management Program
Dr. Lofton is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
530 1st Avenue
Suite 10S
New York, NY 10016
Education & Training
Geisinger Health SystemFellowship, Obesity Medicine and Nutrition Support, 2007 - 2008
Zucker School of Medicine at Hofstra/Northwell at Lenox Hill HospitalResidency, Internal Medicine, 2005 - 2007
Medical College of GeorgiaInternship, Internal Medicine, 2004 - 2005- Medical College of Georgia at Augusta UniversityClass of 2004
Certifications & Licensure
FL State Medical License 2020 - Present
NY State Medical License 2010 - 2026
NJ State Medical License 2024 - 2025
PA State Medical License 2007 - 2016
American Board of Internal Medicine Internal Medicine
American Board of Obesity Medicine Obesity Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery Start of enrollment: 2017 May 22
- A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity Start of enrollment: 2022 Oct 11
- A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight Start of enrollment: 2019 Dec 04
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsGLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study.Babak J Orandi, Yusi Chen, Yiting Li, Garyn T Metoyer, Krista L Lentine
The Lancet. Diabetes & Endocrinology. 2025-03-04 - Glucagon-like peptide-1 receptor agonists discontinuation is higher in individuals with overweight and obesity without type 2 diabetes.Gregory J Grosicki, J Graham Thomas, Nikhil V Dhurandhar, Holly Lofton, Steven B Heymsfield
Diabetes, Obesity & Metabolism. 2025-03-01 - A randomized, double-blind, placebo-controlled trial of weight loss using liraglutide 3.0 mg for weight recurrence after Roux-en-Y gastric bypass.Holly F Lofton, Gabrielle Maranga, Robert Hold, George Fielding, Heekoung Youn
Surgery for Obesity and Related Diseases. 2025-02-01
Press Mentions
The Skinny on Microdosing GLP-1 DrugsMarch 6th, 2025- Focus: Doctors Struggle to Get Wegovy for Older Americans with Heart DiseaseAugust 15th, 2024
- Ozempic Could Be an Accidental Treatment for AddictionMay 24th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
